Atlas Trials

Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

Clinical trial NCT06532617 · RECRUITING

Trial details

NCT number
NCT06532617
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Neoplasms
Start date
2024-09-19
Primary completion
2026-08-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.